Results 21 to 30 of about 15,669 (253)

Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation. [PDF]

PLoS ONE, 2012
Cilostazol is a phosphodiesterase inhibitor that has been shown to inhibit platelet activation. Endothelin is known to be the most potent endogenous growth promoting and vasoactive peptide.
Yoshifumi Kawanabe, Maki Takahashi, Xingjian Jin, Shakila Abdul-Majeed, Andromeda M Nauli, Youssef Sari, Surya M Nauli   +6 more
doaj   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Cilostazol Suppresses IL-23 Production in Human Dendritic Cells via an AMPK-Dependent Pathway

Cellular Physiology and Biochemistry, 2016
Background/Aims: Cilostazol has been previously demonstrated to inhibit IL-23 production in human synovial macrophages via a RhoA/ROCK-dependent pathway.
Quanxing Shi, Zhao Yin, Peilin Liu, Bei Zhao, Zhong Zhang, Shuai Mao, Tengfei Wei, Mengmeng Rao, Liguo Zhang, Shouli Wang   +9 more
doaj   +1 more source

Cilostazol Upregulates Autophagy via SIRT1 Activation: Reducing Amyloid-β Peptide and APP-CTFβ Levels in Neuronal Cells. [PDF]

PLoS ONE, 2015
Autophagy is a vital pathway for the removal of β-amyloid peptide (Aβ) and the aggregated proteins that cause Alzheimer's disease (AD). We previously found that cilostazol induced SIRT1 expression and its activity in neuronal cells, and thus, we ...
Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Sun Sik Bae, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim   +8 more
doaj   +1 more source

ESVM Guideline on peripheral arterial disease [PDF]

, 2019
International ...
, , , Belch, Jill, Boc, Vinko, Brodmann, Marianne, Bulvas, Miroslav, Canning, Caitriona, Carpentier, Patrick H., Chraim, Ali, Colgan, Mary-Paula, Dimakakos, Evangelos, Dorigo, Walter, Frank, Ulrich, Gottsäter, Anders, Heiss, Christian, Houston, Graeme, Kahan, Thomas, Lawall, Holger, Lindstedt, Isak, Madaric, Juraj, Mahe, Guillaume, Martini, Romeo, Mazzolai, Lucia, Nikol, Sigrid, Olinic, Dan Mircea, Pernod, Giles, Poredoš, Pavel, Przywara, Stanislaw, Pécsvárady, Zsolt, Quéré, Isabelle, Righini, Marc, Roztocil, Karel, Schlager, Oliver, Stanek, Agata, Terlecki, Piotr, Vasic, Dragan, Visonà, Adriana, Wautrecht, Jean-Claude   +38 more
core   +5 more sources

Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report

BMC Nephrology, 2018
Background Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as
Hisato Shima, Manabu Tashiro, Satoshi Yamada, Motokazu Matsuura, Kazuyoshi Okada, Toshio Doi, Jun Minakuchi, Shu Kawashima   +7 more
doaj   +1 more source

Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021
Introduction Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol.
Satoshi Saito, Kaori Shinmyozu, Daisuke Kawakami, Miho Yamauchi, Shuhei Ikeda, Yorito Hattori, Rintaro Yamamoto, Naoki Hayakawa, Masafumi Ihara   +8 more
doaj   +1 more source

Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]

, 2010
Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui, De Backer, Tine, De Buyzere, Marc, Van Bortel, Lucas, Vander Stichele, Robert   +4 more
core   +1 more source

Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells.

PLoS ONE, 2015
BackgroundCilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, is known as an anti-platelet drug and acts directly on platelets. Cilostazol has been shown to exhibit vascular protection in ischemic diseases. Although vascular endothelium-derived
Ayako Hashimoto, Michinori Tanaka, Satoshi Takeda, Hideki Ito, Keisuke Nagano   +4 more
doaj   +1 more source

Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks? [PDF]

, 2012
OBJECTIVE: To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke. DATA SOURCES: PubMed and MEDLINE searches were performed (January 1970-September 2011) using the key words cilostazol ...
Ansara, Alex J., Shiltz, Dane L., Slavens, Jennifer B.   +2 more
core   +2 more sources